The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects, according to Julia B. Lewis, MD, of the division of nephrology and hypertension at Vanderbilt University School of Medicine in Nashville. After performing a critical review of the evidence, Dr. Lewis concluded that “a careful review of the data confirms that real uncertainty remains on appropriate BP goals for patients with CKD.” Writing in the Journal of the American Society of Nephrology (2010;21:1086-1092), Dr. Lewis advised individualizing BP control in CKD patients pending additional data, such as that generated by the ongoing Systolic Blood Pressure Intervention (SPRINT) trial in which approximately 10,000 patients will be randomized to achieve various systolic BP targets.

Continue Reading